Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

Fig. 3

Selected safety signals stratified by SGLT2-inhibitor agent. Selected statistically significant safety signals were stratified by SGLT2-inhibitor type (canagliflozin: 10,115 adults and 757 older adults; dapagliflozin: 4,560 adults and 539 older adults; empagliflozin: 7,078 adults and 1,034 older adults). RORs of every drug-AE pair were compared to non-insulin antidiabetic drugs from the full database (88,502 adults and 17,040 older adults). A lower limit of the ROR 95% CI above 1 is the conventional threshold for significant signal detection. Adults are patients aged 18–75, older adults are 75 years or older. ROR- Reporting odds ratio; AKI- Acute kidney injury; CI- Confidence interval; DKA- Diabetic ketoacidosis; GU- genitourinary; NIAD- non-insulin antidiabetic drugs; SGLT2- Sodium-glucose co-transporter 2

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840